Company Filing History:
2 out of 810 
1 out of 1,168 Years Active: 2016-2017
Title: Avital Licht-Murava: Innovator in GSK-3 Inhibitors
Introduction
Avital Licht-Murava is a prominent inventor based in Tel Aviv, Israel. He has made significant contributions to the field of biochemistry, particularly in the development of glycogen synthase kinase-3 (GSK-3) inhibitors. With a total of 2 patents, Licht-Murava's work focuses on innovative peptide inhibitors that have the potential to treat various diseases.
Latest Patents
Licht-Murava's latest patents include novel peptide inhibitors of GSK-3, which are designed to interact with the enzyme's catalytic site. These inhibitors act as disease-selective treatments for conditions associated with increased GSK-3 activity or expression. Each peptide is composed of no more than 15 amino acid residues and features a specific recognition motif that enhances its binding to GSK-3. Additionally, methods for identifying substrate-competitive peptide inhibitors through computational modeling and screening are also disclosed in his patents.
Career Highlights
Throughout his career, Licht-Murava has worked with notable organizations such as Ramot at Tel Aviv University Ltd. and Yeda Research and Development Company Ltd. His research has significantly advanced the understanding of GSK-3 and its role in various diseases.
Collaborations
Licht-Murava has collaborated with esteemed colleagues, including Hagit Eldar-Finkelman and Miriam Eisenstein, who have contributed to his research endeavors.
Conclusion
Avital Licht-Murava's innovative work in developing GSK-3 inhibitors showcases his commitment to advancing medical science. His contributions have the potential to lead to new therapeutic options for patients suffering from conditions linked to GSK-3.